نتایج جستجو برای: jak2 mutation

تعداد نتایج: 294733  

Journal: :American journal of clinical pathology 2011
Jennifer Dunlap Katalin Kelemen Nicky Leeborg Rita Braziel Susan Olson Richard Press James Huang Ken Gatter Marc Loriaux Guang Fan

Myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms are heterogeneous disorders. JAK2 mutation testing and karyotyping are routinely used for diagnosis but have not been incorporated into risk stratification in Philadelphia chromosome-negative myeloproliferative neoplasms. This study correlated cytogenetic abnormalities with disease stage and JAK2 status. A total of 17...

2008
Dirk Erdmann Bertrand Allard Jacqueline Bohn Alain De Pover Andreas Floersheimer Patrizia Fontana Marc Gerspacher Jean Christophe Hau Francesco Hofmann Thomas Radimerski Roman Wille Catherine Zimmermann Patrick Chène

The Janus kinase 2 (JAK2) is a drug target in particular because a missense mutation in this gene (V617F) has been identified in various human diseases. We report here the first kinetic study of the human full-length wild type and V617F JAK2 proteins and of their isolated kinase domain. The kinetic parameters of both full-length proteins are similar revealing that the mutation does not affect J...

Journal: :Blood 2014
Elisa Rumi Daniela Pietra Virginia Ferretti Thorsten Klampfl Ashot S Harutyunyan Jelena D Milosevic Nicole C C Them Tiina Berg Chiara Elena Ilaria C Casetti Chiara Milanesi Emanuela Sant'antonio Marta Bellini Elena Fugazza Maria C Renna Emanuela Boveri Cesare Astori Cristiana Pascutto Robert Kralovics Mario Cazzola

Patients with essential thrombocythemia may carry JAK2 (V617F), an MPL substitution, or a calreticulin gene (CALR) mutation. We studied biologic and clinical features of essential thrombocythemia according to JAK2 or CALR mutation status and in relation to those of polycythemia vera. The mutant allele burden was lower in JAK2-mutated than in CALR-mutated essential thrombocythemia. Patients with...

2010
Lei Gu Xian-Hua Zhu Tapio Visakorpi Kalle Alanen Tuomas Mirtti Tina Bocker Edmonston Marja T. Nevalainen

BACKGROUND Transcription factor Stat5a/b is highly critical for the viability of human prostate cancer cells in vitro and for prostate tumor growth in vivo. Stat5 is constitutively active in clinical prostate cancers but not in the normal human prostate epithelium. Moreover, Stat5a/b activation in prostate cancer is associated with high histological grade of prostate cancer. However, the molecu...

Journal: :Blood 2007
Giovanni Barosi Gaetano Bergamaschi Monia Marchetti Alessandro M Vannucchi Paola Guglielmelli Elisabetta Antonioli Margherita Massa Vittorio Rosti Rita Campanelli Laura Villani Gianluca Viarengo Elisabetta Gattoni Giancarla Gerli Giorgina Specchia Carmine Tinelli Alessandro Rambaldi Tiziano Barbui

Few investigators have evaluated the usefulness of the JAK2 V617F mutation for explaining the phenotypic variations and for predicting the risk of major clinical events in primary myelofibrosis (PMF). In a transversal survey we assayed by allele-specific polymerase chain reaction (PCR) the JAK2 V617F mutational status in 304 patients with PMF. Multiple DNA samples were collected prospectively f...

Journal: :Blood 2013
Adam J Mead Onima Chowdhury Christian Pecquet Alexandra Dusa Petter Woll Deborah Atkinson Adam Burns Joannah Score Michelle Rugless Ruth Clifford Simon Moule Nicola Bienz Paresh Vyas Nick Cross Rosemary E Gale Shirley Henderson Stefan N Constantinescu Anna Schuh Sten Eirik W Jacobsen

The association between somatic JAK2 mutation and myeloproliferative neoplasms (MPNs) is now well established. However, because JAK2 mutations are associated with heterogeneous clinical phenotypes and often occur as secondary genetic events, some aspects of JAK2 mutation biology remain to be understood. We recently described a germline JAK2V617I mutation in a family with hereditary thrombocytos...

Journal: :Blood 2006
Takefumi Ishii Edward Bruno Ronald Hoffman Mingjiang Xu

The JAK2(V617F) mutation has been shown to occur in the overwhelming majority of patients with polycythemia vera (PV). To study the role of the mutation in the excessive production of differentiated hematopoietic cells in PV, CD19+, CD3+, CD34+, CD33+, and glycophorin A+ cells and granulocytes were isolated from the peripheral blood (PB) of 8 patients with PV and 3 healthy donors mobilized with...

Journal: :Japanese journal of clinical oncology 2009
Junko H Ohyashiki Hisashi Hisatomi Syoko Shimizu Maki Sugaya Kazuma Ohyashiki

OBJECTIVE Polycythemia vera (PV) is a clonal myeloproliferative neoplasia associated with the activation of the Janus-activating kinase 2 (JAK2) mutation. The aim of this study is to identify clonal expansion of exon 12 mutations. METHODS We performed DNA sequencing of the JAK2 exon 12 after TA-cloning in JAK2-V617F-negative and JAK2-V617F-positive PV patients. RESULTS AND CONCLUSIONS We fo...

2015
Paolo Catarsi Vittorio Rosti Giacomo Morreale Valentina Poletto Laura Villani Roberto Bertorelli Matteo Pedrazzini Michele Zorzetto Giovanni Barosi

BACKGROUND Primary myelofibrosis (PMF) is an acquired clonal disease of the hematopoietic stem cell compartment, characterized by bone marrow fibrosis, anemia, splenomegaly and extramedullary hematopoiesis. About 60% of patients with PMF harbor a somatic mutation of the JAK2 gene (JAK2-V617F) in their hematopoietic lineage. Recently, a splicing isoform of JAK2, lacking exon 14 (JAK2Δ14) was des...

2010
Dong Wook Jekarl Sang Bong Han Myungshin Kim Jihyang Lim Eun-Jee Oh Yonggoo Kim Hee-Je Kim Woo-Sung Min Kyungja Han

BACKGROUND The JAK2 V617F mutation has been noted in the cases of polycythemia vera, essential thrombocythemia, and primary myelofibrosis patients. This mutation occurs less frequently in acute myeloid leukemia (AML) and other hematologic diseases, such as myelodysplastic syndrome (MDS); myelodysplatic syndrome/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U); and refractory anemia with ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید